GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » ROA %

GeneDx Holdings (GeneDx Holdings) ROA % : -19.91% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. GeneDx Holdings's annualized Net Income for the quarter that ended in Mar. 2024 was $-81.0 Mil. GeneDx Holdings's average Total Assets over the quarter that ended in Mar. 2024 was $406.6 Mil. Therefore, GeneDx Holdings's annualized ROA % for the quarter that ended in Mar. 2024 was -19.91%.

The historical rank and industry rank for GeneDx Holdings's ROA % or its related term are showing as below:

WGS' s ROA % Range Over the Past 10 Years
Min: -105.06   Med: -78.41   Max: -29.97
Current: -29.97

During the past 5 years, GeneDx Holdings's highest ROA % was -29.97%. The lowest was -105.06%. And the median was -78.41%.

WGS's ROA % is ranked worse than
82.24% of 670 companies
in the Healthcare Providers & Services industry
Industry Median: 1.255 vs WGS: -29.97

GeneDx Holdings ROA % Historical Data

The historical data trend for GeneDx Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneDx Holdings ROA % Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
- -95.91 -60.91 -105.06 -38.64

GeneDx Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.08 -36.58 -37.85 -24.66 -19.91

Competitive Comparison of GeneDx Holdings's ROA %

For the Health Information Services subindustry, GeneDx Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneDx Holdings's ROA % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, GeneDx Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's ROA % falls into.



GeneDx Holdings ROA % Calculation

GeneDx Holdings's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-175.767/( (490.942+418.756)/ 2 )
=-175.767/454.849
=-38.64 %

GeneDx Holdings's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-80.956/( (418.756+394.528)/ 2 )
=-80.956/406.642
=-19.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


GeneDx Holdings  (NAS:WGS) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-80.956/406.642
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-80.956 / 249.688)*(249.688 / 406.642)
=Net Margin %*Asset Turnover
=-32.42 %*0.614
=-19.91 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


GeneDx Holdings ROA % Related Terms

Thank you for viewing the detailed overview of GeneDx Holdings's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneDx Holdings (GeneDx Holdings) Business Description

Traded in Other Exchanges
N/A
Address
333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.
Executives
Kareem Saad officer: Chief Business Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Katherine Stueland director, officer: Chief Executive Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Kevin Feeley officer: Chief Financial Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Keith A. Meister director, 10 percent owner C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White officer: Chief People Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp director, 10 percent owner C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Corvex Management Lp director, 10 percent owner 667 MADISON AVENUE, NEW YORK NY 10065
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137